In a high-stakes twist in the pharmaceutical legal arena, Jazz Pharmaceuticals has agreed to shell out a staggering $145 million to settle claims that it orchestrated an anticompetitive scheme with rival Hikma Pharmaceuticals to delay the launch of cheaper generic versions of its lucrative narcolepsy drug, Xyrem.

The settlement, disclosed Tuesday in a U.S. Securities and Exchange Commission Form 8-K, marks a dramatic turning point in long-running multidistrict litigation that alleged Jazz used “pay-for-delay” tactics to freeze competitors out of the market — a strategy critics liken to keeping a velvet rope around a monopoly.

The Deal: A $145M Exit from a Legal Quagmire

Jazz revealed that it reached a preliminary settlement agreement with a proposed class of indirect Xyrem purchasers — entities that either paid for or reimbursed costs of the drug — in select states. The deal would cover all claims against Jazz concerning its past patent litigation settlements with generic drugmakers.

The pharmaceutical giant, based in Ireland, maintains its denial of any wrongdoing, and the settlement is still subject to court approval.

The Allegations: Reverse Payments and Market Blockades

At the heart of the litigation were claims that Jazz entered into reverse payment agreements — effectively, cash incentives to delay competition — with Hikma Pharmaceuticals, the first company to file for approval to sell a generic version of Xyrem. Similar deals with later filers were also alleged, locking out alternatives in what plaintiffs claimed was an effort to illegally preserve a monopoly.

The legal battle — filed as In re: Xyrem (sodium oxybate) Antitrust Litigation, case number 3:20-md-02966 — is being handled in the U.S. District Court for the Northern District of California under Judge Richard Seeborg.

Class Action Landscape Shifts as Players Exit the Stage

Back in May 2023, Judge Seeborg certified the class and gave the green light to settlements involving Amneal Pharmaceuticals LLC and Lupin Pharmaceuticals Inc., who collectively agreed to pay $3.4 million to bow out. That left Jazz and Hikma standing alone in the litigation crosshairs — until this week.

Jazz’s decision to settle follows reports of a Zoom hearing last month, during which Jazz and a certified insurer class revealed they’d reached a settlement-in-principle. However, Hikma, along with opt-out plaintiffs like Humana Inc. and Molina Healthcare Inc., remain active players in the legal fray.

Trial Trajectory: One Path Clears, Another Looms

Judge Seeborg on Tuesday clarified the direction of the case, stating that the looming May 19 trial would proceed only between the class and Hikma, given Jazz’s exit and unresolved claims by the opt-out insurers.

"The structure of that trial is presently uncertain," he noted, emphasizing the court's desire to avoid confusion and prejudice that could arise from blending multiple plaintiff groups. He underscored that evidence from opt-out plaintiffs — aimed at proving Jazz’s alleged monopoly — would only cloud the jury’s understanding.

"Ultimately, less is more," Seeborg wrote in his order, favoring a "streamlined, relatively simpler trial" that allows each party their day in court without entangling overlapping claims.

Legal Armies Assembled: Counsel in the Spotlight

This heavyweight litigation has drawn a who’s who of legal talent:

• The class is represented by attorneys from Girard Sharp LLP and Motley Rice LLC.

• Opt-out insurers such as Humana, UnitedHealthcare, and Blue Cross Blue Shield of Florida are represented by Schneider Wallace, Lowey Dannenberg, Boies Schiller Flexner LLP, and Zelle LLP.

• Jazz Pharmaceuticals has enlisted Skaggs Faucette LLP and Williams & Connolly LLP.

• Hikma Pharmaceuticals is defended by White & Case LLP.

The Big Picture: Monopoly Allegations Cast Long Shadows

The lawsuit has spotlighted long-standing concerns around "pay-for-delay" settlements, which critics argue hinder access to affordable generics and inflate drug prices. Xyrem, a blockbuster treatment for narcolepsy, has been at the center of these concerns due to its high cost and limited competition.

While Jazz exits stage left with a hefty price tag, the remaining players prepare for a courtroom showdown that could further reshape how the pharmaceutical industry navigates the thin line between patent protection and market manipulation.

One thing is certain: the drama over Xyrem is far from its final act.